The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...

Spravato had been cleared in the United States ... Health News // 1 day ago Convenience stores eyed as way to provide morning-after pill St. PAUL, Minn., May 27 (UPI) -- Women's health advocates ...

Breakthroughs, discoveries, and DIY tips sent every weekday. Terms of Service and Privacy Policy. Johnson & Johnson has announced the FDA’s approval of a first-of ...

Spravato (esketamine) is a nasal spray used for depression and was approved by the FDA in 2019. It is specifically for treatment-resistant depression, meaning depression symptoms that have not ...

On Tuesday, the government agency announced Spravato nasal spray, also known as esketamine, can now be used "for the treatment of depression in adults who have tried other antidepressant ...

Credit: Johnson & Johnson. The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, placebo-controlled, phase 4 TRD4005 trial.

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression ...

When Dr. Husseini Manji was developing the first-in-class depression medication Spravato at Johnson & Johnson he encountered plenty of naysayers. “A lot of people didn’t think it would work ...

The U.S. Food and Drug Administration has expanded its approval of Spravato, an antidepressant nasal spray. The drug is now cleared for use as a standalone treatment for depression. Spravato is ...

It is a legal medical treatment. The 34-year-old doctor from Denver is taking Spravato, a medicine derived from club-drug ketamine that is approved for treating his depression.

The Food and Drug Administration approved Johnson & Johnson's nasal spray to be used alone in adults with a major depressive disorder that is difficult to treat, as sales of the drug grow.